Purchase Order 75N93021P00855
- Not listed
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), awarded a $54,930.70 firm fixed-price purchase order to Becton, Dickinson and Company (BD) for the procurement of 64 specific BD Biosciences brand conjugated antibodies and laboratory reagents. The contract, which has no set-aside designation, was issued through a Request for Quotes (RFQ-NIAID-25-2258428) under the Simplified Acquisition Procedures of the Federal Acquisition...
- On September 16, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) awarded a purchase order valued at $47,198.82 to Becton, Dickinson and Company (BD), through its BDB Division operating as BD Biosciences, for BD Reagents. This firm fixed-price contract was awarded without a small business set-aside on a competitive basis. The award represents a purchase order action to procure reagents from BD, a global medical technology company specializing in flow cytometry, cell...
- BD Biosciences has been awarded a firm fixed price purchase order totaling $73,666.80 by the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The contract has no set-aside designation. BD Biosciences will provide various flow cytometers, lasers, and associated equipment in support of biomedical research being conducted by the agency. Specifically, the contract calls for BD BIOSCIENCES SYMPHONY S6 flow cytometers, FACSTATION cell sorters, and various lasers...
- This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Becton, Dickinson & Co (BD), a large medical technology manufacturer. The contract is for the provision of flow cytometry antibody reagents, with a ceiling value of $16,108.30 and a period of performance ending on July 31, 2025. The contract was awarded on a full and open competition basis without any set-aside designation. BD is a...
- This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Becton, Dickinson and Company (BD) for the purchase of flow cytometric equipment. The $266,050.00 firm fixed-price contract has an ultimate completion date of August 26, 2016. The award was not set aside for any specific business type. BD is a global medical technology company that provides a wide range of goods and services to U.S....
- This contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, to Becton, Dickinson and Company (BD) for the purchase of a brand name or equal flow cytometer and high throughput sampler. The total ceiling value of the contract is $261,786.70. The contract is a firm fixed price purchase order with an ultimate completion date of September 19, 2019. The requested items are for NIAID's Laboratory of...
- The National Institute of Allergy and Infectious Diseases awarded a purchase order to Becton, Dickinson and Company for $362,388.00 on February 2, 2015, with ultimate completion on March 31, 2020. No small business set-aside was used. The order is firm fixed price. Place of performance is Bethesda, Maryland. The awardee, operating as BD Biosciences, supplies flow cytometry systems, laboratory instrumentation, reagents, and associated consumables and technical support services to federal...
- <p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Becton, Dickinson and Company (BD Biosciences) for $41,964.74 on July 21, 2015, for a flow cytometer. Performance is located in San Jose, California. The order carries a firm fixed price and an ultimate completion date of August 20, 2015. No set-aside was applied.</p>
- Becton, Dickinson and Company, operating through its BD Biosciences division, was awarded a $13,883.23 firm fixed-price purchase order by the National Institute of Allergy and Infectious Diseases (NIAID) on March 10, 2022, with a completion date of April 30, 2022. The contract covers pre-contract inspection and recertification services for an LSR Fortessa flow cytometry system, a critical research instrument used in biomedical analysis and infectious disease research. The work is to be performed...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Becton, Dickinson and Company (BD) for a flow cytometer service contract. The contract, which is not set aside, has a ceiling value of $112,011.36 and a period of performance through December 31, 2017. BD, a global medical technology company, is providing flow cytometry instruments, reagents, and associated maintenance services to...
The National Institute of Allergy and Infectious Diseases awarded a purchase order to Becton, Dickinson and Company (BD Biosciences) on June 23, 2021, for flow cytometry antibodies with a ceiling value of $16,700.58. This firm fixed-price contract represents a de-obligation action intended to administratively expend unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) in preparation for the September 30, 2026 closing of the period of availability for these fiscal year funds. The ultimate completion date was June 25, 2021, with performance taking place in San Jose, California. No small business set-aside was used in this award. BD Biosciences, operating as a division of parent company Becton, Dickinson and Company, is a global medical technology manufacturer specializing in flow cytometry systems and associated laboratory reagents. The company maintains an extensive federal contract portfolio serving multiple National Institutes of Health components, the Department of Veterans Affairs, and other healthcare agencies. NIAID's selection of BD for this antibody procurement reflects the company's established position as a critical supplier of specialized flow cytometry consumables and reagents essential to biomedical research operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00001 | Funding Only Action | 0$ | 4/28/26 | |
| Not listed | Not listed | $16.7k | 6/23/21 |